Rezatapopt has been granted FDA Fast Track designation for the treatment of patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation and is currently undergoing evaluation in the tumor-agnostic PYNNACLE Phase 2 clinical trial (NCT04585750) to generate data supporting its regulatory approval. The gene discussed is TP53; the disease is neoplasm.